2023-505006-41-00CompletedPhase 1
Study is designed to assess the safety and tolerability of ceralasertib at increasing doses in combination with other anti-cancer treatment in patients with advanced tumours
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- AstraZeneca AB
- Enrollment
- 100
- Locations
- 4
Study Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 65+ years (65+ Years, 18-64 Years)
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Laura Taylor
Scientific
AstraZeneca AB
Study Sites (4)
Loading locations...
Similar Trials
Recruiting
Phase 1
A study to investigate the safety and tolerability of SDL-M1 nanoparticles in healthy volunteers2024-518889-27-00SmartDyeLivery GmbH48
Recruiting
Phase 1
A study investigating the safety, tolerability, metabolism, and elimination of INE963, a new compound in the treatment of malaria.Malaria2024-516911-26-00Novartis Pharma AG94
Recruiting
Phase 1
Study to evaluate the safety, tolerability, maximum tolerated dose and clinical activity of TNB-383B when given to patients with multiple myeloma2023-506993-11-00AbbVie Deutschland GmbH & Co. KG22
Withdrawn
Phase 1
A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of a pDNA Vaccine Candidate Against COVID-19 in Healthy Adults2023-505135-12-00Imam Abdulrahman Bin Faisal University60
Recruiting
Phase 1
A study to assess the safety, tolerability, uptake and efficacy of VMX-C001 in healthy volunteers.2023-507059-32-00VarmX B.V., VarmX B.V.48